Microsize
Microsize is a US-headquartered pharmaceutical CDMO specializing in jet milling, micronization, and particle engineering for poorly soluble APIs, operating three FDA-inspected cGMP facilities across 100,000+ sq ft and serving small biotechs through large pharma from feasibility to commercial supply.
- Company typePrivate
- Founded2022
- HeadquartersPhiladelphia, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Microsize does
Microsize is a US-headquartered pharmaceutical contract development and manufacturing organization (CDMO) specializing in particle size reduction, powder classification, and analytical services for small-molecule active pharmaceutical ingredients (APIs) and excipients. The company addresses bioavailability and dissolution challenges for poorly soluble compounds through jet milling and micronization — proprietary equipment designed and built in-house — capable of reducing particles to under 10 microns with ~1 micron variance. Microsize operates three FDA-inspected cGMP facilities totaling over 100,000 sq ft in Quakertown, Pennsylvania, and acquired a fourth GMP facility in Monteggio, Switzerland (Micro-Macinazione) from Lonza in May 2026, creating a dual US-European particle engineering platform.
The company offers end-to-end services spanning feasibility studies (as little as 1-5 grams of API), Phase I-III clinical manufacturing, and commercial production campaigns at multi-metric-ton scale. Differentiated capabilities include Co-Jet Milling (combined size reduction and blending), HPAPI containment qualified to OEB 6 (down to 50 ng/m³), air-swept turbo classification for hydrate stability, and advanced analytical characterization (XRPD, DSC, TGA, DVS, laser diffraction). Microsize has expanded beyond toll micronization into a broader particle engineering ecosystem through partnerships with AustinPx (KinetiSol), The Solubility Company (SPA platform licensing — Microsize is the first US licensee), Persist AI (Micromill platform), and Aspire Biopharma (sublingual alprazolam and aspirin development).
Microsize generates revenue through project-based professional services contracts with pharmaceutical companies ranging from small biotechs to large pharma, as well as other CDMOs and functional excipient manufacturers. Pricing is quote-based, dependent on API type, potency, batch size, and development phase. GTM is high-touch, enterprise field sales with direct technical engagement, supplemented by conference presence (CPhI, ChemOutsourcing), technical whitepapers, and LinkedIn-driven brand building. The company is privately held, launched as an independent entity in July 2022 after separation from Lonza, and inherits the 30-year operational heritage of predecessor Powdersize Inc.
Microsize firmographics
Firmographics- Name
- Microsize
- Legal name
- Microsize LLC
- Website
- https://microsize.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Microsize is a US-headquartered pharmaceutical CDMO specializing in jet milling, micronization, and particle engineering for poorly soluble APIs, operating three FDA-inspected cGMP facilities across 100,000+ sq ft and serving small biotechs through large pharma from feasibility to commercial supply.
- Ownership category
- akta.pro rank
Microsize industry classification
Industry- Product category
- Pharmaceutical CDMO Services
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Plastics Products, Nec (3089)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
Keywords
Where Microsize is headquartered
LocationHeadquarters
- HQ city
- Philadelphia
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Microsize business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Contract Manufacturing Services (CDMO): Microsize provides contract development and manufacturing organization services for pharmaceutical micronization and particle size reduction. Revenue is generated through project-based contracts spanning feasibility studies through commercial production campaigns. The company charges for processing services based on project scope, material quantities, and complexity. Services are provided to small biotechs, mid-size pharmaceutical companies, and large pharma organizations.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Microsize product offering
Product offeringCore offering
Microsize is a US-based pharmaceutical contract development and manufacturing organization (CDMO) providing cGMP micronization and particle size reduction services. The company processes APIs and excipients from grams to multi-metric tons, including highly potent compounds, through three FDA-inspected facilities. Core offerings include particle size reduction (micronization/milling), particle classification, analytical characterization, and high-potency containment services for drug developers addressing dissolution and bioavailability challenges.
Differentiator
Problem solved
Functional benefit
Brands
- Micromill: First-of-its-kind early-stage formulation platform enabling drug development decisions with milligrams of API, developed in partnership with Persist AI and Micromacinazione.
Products and services
- Micronization & Particle Size Reduction Services
- Particle Classification Services
- Analytical Characterization Services
- High Potency Containment Services
- Micromill Platform
- SPA Platform Licensing
Quantifiable outcome
- Feasibility assessments completed in one day with minimal API (as little as 1-5 grams)
- +3 more outcomes
Companies that use Microsize
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Microsize technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Microsize partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core.
- Persist AIcoreStrategic collaboration to launch 'Micromill' platform, the world's first integrated system enabling oral formulation decision-making using only milligrams of API. Combines Micmac's SSM20 mini mill with Persist AI's AI-driven experimentation and process analytical technology.
- Aspire BiopharmacorePartnership to develop first-ever sublingual alprazolam powder formulation for faster anxiety relief. Phase 1 clinical trial planned for mid-2026, targeting a medication with over 15.8 million US prescriptions in 2023.
- Schedio GroupcoreJoint acquisition of Micro-Macinazione (Micmac) from Lonza to establish integrated European-American network for advanced particle engineering. Schedio contributes process equipment and containment technologies while Microsize provides CDMO expertise. Transaction closed May 2026.
- The Solubility CompanycoreMicrosize became the first US licensee for The Solubility Company's SPA platform, a novel solubility measuring technology. Strategic investment to accelerate US expansion of this disruptive technology.
- AFT PharmaceuticalscoreExpanded CDMO relationship for commercial supply of MAXIGESIC/COMBOGESIC products with investments in capacity expansion.
- Cerus CorporationcoreExpanded CDMO relationship with Cerus Corporation for pharmaceutical manufacturing services.
- AustinPxcorePartnership on KinetiSol technology for novel particle size technology, enabling development of products using this advanced formulation approach.
Scale indicators8 records
Recent moves7 records
Expansion highlights5 records
Microsize competitors and assessment
Company assessmentDirect peers
- Halo Pharma: Halo Pharma is a specialty CDMO focused on oral solid dosage form development and manufacturing. It competes with Microsize for bioavailability-limited drug product work where particle engineering and formulation overlap, particularly for small and mid-size pharma customers.
- Hovione: Hovione is a Portugal-headquartered global CDMO with deep particle engineering and jet milling capabilities for small-molecule APIs. It competes most directly with Microsize across micronization, HPAPI containment, and bioavailability-enhancement services, serving similar biotech-to-big-pharma customers with overlapping technology offerings.
- Ascendia Pharmaceuticals: Ascendia Pharmaceuticals is a specialty CDMO focused on nano-milling and formulation development for poorly soluble compounds. It directly competes with Microsize in providing bioavailability-enhancement and particle engineering services, often at similar early-stage customer touchpoints.
- Lubrizol Life Sciences (Particle Sciences): Lubrizol Life Sciences, through its Particle Sciences business, is a CDMO focused on particle engineering, formulation development, and drug product manufacturing. It directly competes with Microsize in micronization and bioavailability-enhancement services for poorly soluble APIs across a similar customer base of small to mid-size pharma.
Broad incumbents
- Lonza: Lonza is one of the largest global CDMOs and historically operated the Quakertown and Micro-Macinazione facilities that Microsize acquired. While Lonza offers micronization as part of a far broader CDMO portfolio, its scale and breadth make it a frequent alternative or competitor for bioavailability-limited small-molecule programs.
- Evotec: Evotec is a global contract development and manufacturing organization with capabilities spanning drug substance, drug product, and integrated pharmaceutical services. It competes with Microsize for formulation and bioavailability-enhancement projects, particularly with European biotech customers after Microsize's Micro-Macinazione expansion.
- Catalent: Catalent is a large global CDMO offering a wide range of drug product services including particle engineering, bioavailability enhancement, and HPAPI handling. It competes with Microsize at the high end of the market by bundling micronization into broader end-to-end development and manufacturing contracts.
- Thermo Fisher Scientific (Patheon): Thermo Fisher's pharma services business, built around Patheon, is a major global CDMO offering drug substance, drug product, and bioavailability-enhancement services. It is a broad incumbent competitor for Microsize's biotech and large pharma customers across micronization-adjacent formulation work.
- Eurofins CDMO: Eurofins operates a CDMO and contract testing portfolio that overlaps with Microsize's analytical characterization and formulation-support offerings. It is a broader incumbent that competes for outsourced pharmaceutical development and quality services across both US and European markets.
Emerging players
- Aprecia Pharmaceuticals: Aprecia is a specialty pharma company and CDMO using binder-jetting 3D printing for oral dosage forms. It is an emerging player in the broader particle-engineering and bioavailability space, intersecting with Microsize's territory through novel oral drug delivery approaches for poorly soluble compounds.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key highlights7 records
Customer concentration
Microsize social profiles
Digital presenceMicrosize financial estimates
Financial estimateRevenue estimate
Valuation estimate
Microsize leadership team
Management profileNumber of profiles
Profiles4 records
Microsize subsidiaries and ownership
Company hierarchySubsidiaries2 records
Microsize funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Microsize M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Microsize
What does Microsize do?
Microsize is a US-based pharmaceutical contract development and manufacturing organization (CDMO) providing cGMP micronization and particle size reduction services. The company processes APIs and excipients from grams to multi-metric tons, including highly potent compounds, through three FDA-inspected facilities. Core offerings include particle size reduction (micronization/milling), particle classification, analytical characterization, and high-potency containment services for drug developers addressing dissolution and bioavailability challenges.
Is Microsize a public or private company?
Microsize is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Microsize founded?
Microsize was founded in 2022. It employs 11 to 50 people.
Where is Microsize based?
Microsize is headquartered in Philadelphia, United States, in the North America region.
How does Microsize make money?
One revenue line is on record: contract Manufacturing Services (CDMO).
Who are Microsize's main competitors?
Direct peers on record are Halo Pharma, Hovione, Ascendia Pharmaceuticals and Lubrizol Life Sciences (Particle Sciences). Broad incumbents are Lonza, Evotec, Catalent, Thermo Fisher Scientific (Patheon) and Eurofins CDMO. Aprecia Pharmaceuticals is listed as an emerging player.
Does Microsize have an API?
No public API is recorded for Microsize.
What industry is Microsize in?
Microsize's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 3254 and its SIC code is 3089.